Visselhovede

This research aims to assess how satisfied people with Multiple Sclerosis (MS) are after receiving subcutaneous (under the skin) injections of ocrelizumab over a period of 12 months. The study focuses on participants diagnosed with relapsing-remitting MS (RMS) or primary progressive MS (PPMS) according to 2017 McDonald criteria, who are starting ocrelizumab treatment for the first time. The main goal is to understand participant satisfaction using a special questionnaire designed for subcutaneous therapy administration. Participants will receive ocrelizumab as an injection under the skin, with the exact dosing and schedule determined by their treating physician following local medical guidelines. This observational study does not change standard care but monitors patients throughout their treatment with ocrelizumab. During the study, participants will complete the Therapy Administration Satisfaction Questionnaire for subcutaneous treatment after 12 months to measure their satisfaction. Researchers will also observe and record any relevant clinical information. The total study duration for each participant is 12 months, during which their experience and outcomes with ocrelizumab are carefully tracked.

Researchers are conducting a registry to study the performance and short-term safety of Resorbable Magnesium Scaffolds (RMS) in patients with coronary artery disease. This registry follows the ESC/EACTS guidelines and evaluates these devices in real-world use based on their intended instructions without additional medical exclusion criteria. The study involves the use of two types of RMS devices, Magmaris and Freesolve, which are designed to improve the diameter of native coronary artery lesions in patients with symptomatic coronary artery disease. These devices are used where the vessel size matches the scaffold size, and the lesion length is shorter than the scaffold length. Participants will be monitored according to the registry protocols, focusing on outcomes such as Target Lesion Failure over 12 months. The study observes the clinical use and safety of these devices in typical treatment settings without additional restrictions. Patient follow-up and data collection occur throughout the study duration to assess device performance.

Researchers are evaluating the safety and effectiveness of the SELUTION SLR14 drug-eluting balloon compared to a plain (uncoated) balloon angioplasty for treating peripheral arterial disease in below-the-knee arteries of patients with chronic limb-threatening ischemia. The study aims to show better treatment success with the drug-eluting balloon while maintaining similar safety. Eligible patients have significant artery narrowing and symptoms lasting more than two weeks. Participants will receive either the SELUTION SLR14 drug-eluting balloon or the plain balloon during a non-surgical procedure where a catheter inflates the balloon to open narrowed arteries below the knee. The study focuses on lesions in specific below-the-knee arteries and follows strict criteria for lesion size, location, and vessel condition. The treatments are delivered through minimally invasive catheter techniques. During the study, participants will be monitored for safety up to 30 days and for treatment effectiveness over 6 months. Assessments include imaging to confirm artery opening, clinical evaluations, and follow-up visits to track healing and limb function. The study also observes for complications or adverse events to ensure participant safety throughout the trial.